ClinicalTrials.gg
CompletedNCT05037097Updated Oct 15, 2025Results posted

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

A Phase 1/2 interventional study of ARCT-165 and ARCT-154 in COVID-19, SARS-CoV-2 Infection and Corona Virus Infection, sponsored by Arcturus Therapeutics, Inc.. Completed at 4 sites in 3 countries. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by Arcturus Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
710th of 1,322
72 · median 92
Started
2021
with 503 others
Phase 1/2
62 of 1,860
4 open now
Registered
1,250th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 710th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 62 in phase 1/2, and was the 1,250th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.

Read the detailed description

The study will initially enroll approximately 72 adult participants into 2 cohorts (A and B). Cohort A is further sub-divided into two sub-cohorts which include 12 participants who are seronegative, not previously vaccinated at screening (Sub-cohort A1) and 24 participants who are seropositive, not previously vaccinated at screening (Sub-cohort A2).

Within the first cohort (Cohort A), Sub-cohort A1 will include a total of 12 adult participants ≥21 to ≤65 years of age who have not been previously vaccinated with a SARS-CoV-2 vaccine. Sub-cohort A2 will include a total of 24 adult participants ≥21 to ≤65 years of age who have not been previously vaccinated with a SARS-CoV-2 vaccine. Study vaccines will be given as 2 doses separated by 28 days.

The second cohort (Cohort B) will include a total of 36 adult participants ≥21 to ≤65 years of age who have been previously vaccinated (5 months or longer prior to study enrollment) with SARS-CoV-2 vaccine. Study vaccines will be given as single doses.

Additional cohorts may increase the age range of participants up to 80 years of age.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2 Infection
  • Corona Virus Infection

Keywords

  • SARS-CoV-2 Vaccine
  • Coronavirus Virus Diseases
  • RNA COVID-19
  • COVID-19 Vaccine Arcturus
  • Self Amplifying RNA Vaccine
  • Variants of Concern
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals who:

  1. Are able to provide consent
  2. Agree to comply with all study visits and procedures
  3. Are willing and able to adhere to study restrictions
  4. Are sexually active and willing to adhere to requirements
  5. Are male, female, or transgender ≥21 to ≤80 years of age
  6. For the previously vaccinated groups only, received 2 doses of SARS-CoV-2 vaccine 5 months or longer prior to study enrollment

Exclusion criteria

Exclusion Criteria:

Individuals who:

  1. For the unvaccinated groups only, previously received any or authorized MERS-CoV, SARS-CoV, and SARS-CoV-2 vaccines (including ARCT-021)
  2. For the previously vaccinated groups only, previously received BNT162b2 but have not received 2 doses within at least 5 months prior to study enrollment
  3. Are planning to receive other COVID-19 vaccines during the study period
  4. Recently received other vaccines
  5. Have a fever or are feeling sick close to the time of the first study vaccination
  6. Have a known history of COVID-19 disease or asymptomatic SARS-CoV-2 infection
  7. Are pregnant or breastfeeding
  8. Have had a severe reaction to previous vaccines
  9. Have a severe or uncontrolled disease(s) that may interfere with the interpretation of the study
  10. Have some respiratory diseases
  11. Have some significant heart diseases
  12. Have some neurological conditions
  13. Have sickle cell disease or some other blood disorders
  14. Have had a major surgery within the past 6 months
  15. Have a history of chronic liver disease
  16. Have a history of disease or immunodeficiency
  17. Have received allergy injections, interferon, immunomodulators, cytotoxic drugs or other similar toxic drugs.
  18. Have received blood products
  19. Have a positive test for or C or
  20. Have uncontrolled hypertension
  21. Have had cancer except for cancers that were treated and that have low risk of returning
  22. Are obese
  23. Are Investigator site staff members, employees of Arcturus or the contract research organization (CRO) directly involved in the conduct of the study, or site staff members otherwise supervised by the Investigator or immediate family members of any of the previously mentioned individuals
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Study Group 1, Adult Participants Seronegative, Not Previously Vaccinated randomized to ARCT-165

    Participants will receive one dose of ARCT-165 on Day 1 and one dose of ARCT-165 on Day 29

    Biological: ARCT-165

  • Experimental
    Study Group 2, Adult Participants Seronegative, Not Previously Vaccinated randomized to ARCT-154

    Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29

    Biological: ARCT-154

  • Experimental
    Study Group 3, Adult Participants Seronegative, Not Previously Vaccinated to receive ARCT-021

    Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29

    Biological: ARCT-021

  • Experimental
    Study Group 4, Adult Participants Seropositive, Not Previously Vaccinated to receive ARCT-021

    Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29

    Biological: ARCT-021

  • Experimental
    Study Group 5, Adult Participants Seropositive, Not Previously Vaccinated randomized to ARCT-154

    Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29

    Biological: ARCT-154

  • Experimental
    Study Group 6, Adult Participants Previously Vaccinated randomized to receive ARCT-165

    Participants will receive one dose of ARCT-165 on Day 1

    Biological: ARCT-165

  • Experimental
    Study Group 7, Adult Participants Previously Vaccinated randomized to receive ARCT-154

    Participants will receive one dose of ARCT-154 on Day 1

    Biological: ARCT-154

  • Experimental
    Study Group 8, Adult Participants Previously Vaccinated randomized to receive ARCT-021

    Participants will receive one dose of ARCT-021 on Day 1

    Biological: ARCT-021

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs)

    Solicited local AEs were defined as injection site erythema, injection site pain, injection site induration, and injection site tenderness. Solicited systemic AEs were defined as arthralgia, chills, diarrhea, dizziness, fatigue, fever (categorized by measured body temperature), headache, myalgia, nausea and vomiting. Data are reported for the number of participants with solicited local and solicited systemic AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to Day 8 (7 days after first vaccine administration for Cohorts A1, A2 and B), and up to Day 36 (7 days after second vaccine administration for Cohorts A1 and A2)

  2. Number of Participants Reporting Unsolicited AEs

    Unsolicited AEs were defined as any spontaneously reported or discovered AE. Data are reported for the number of participants with unsolicited AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to Day 29 (28 days after vaccine administration for Cohort B), and up to Day 57 (up to 28 days after each vaccine administration for Cohorts A1 and A2)

  3. Number of Participants Reporting Medically Attended Adverse Events (MAAEs), AEs Leading to Discontinuation From Study Vaccine/Study Withdrawal, or Serious Adverse Events (SAEs)

    An MAAE was an AE that led to an unscheduled visit (including a telemedicine visit) with a health care provider (HCP) (e.g., nurse, nurse practitioner, physician's assistant, physician), including visits to a study site for unscheduled assessments (e.g., rash assessment, abnormal laboratory follow up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the study site (e.g., urgent care, primary care physician). An SAE was defined as any event that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Through Final Visit (365 days after last study vaccine dose); up to a maximum of approximately 394 days

  4. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Concentration (GMC)

    Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral D614G variant. Data are reported in international units per milliliter (IU/mL).

    Time frame: Baseline, Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2; Baseline, Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  5. SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMC

    Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral B.1.351 (beta) variant. Data are reported in arbitrary units per milliliter (AU/mL).

    Time frame: Baseline, Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2; Baseline, Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  6. SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Fold Rise (GMFR)

    Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral D614G variant.

    Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  7. SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMFR

    Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral B.1.351 (beta) variant.

    Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  8. Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral D614G Variant)

    Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G variant.

    Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  9. Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral B.1.351 [Beta] Variant)

    Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral B.1.351 (beta) variant.

    Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  10. GMC Ratio (ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154)

    Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154. Data are reported for the ARCT-165 and ARCT-021 arms (vs ARCT-154 values).

    Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  11. GMC Ratio (ARCT-021 vs ARCT-165 Cohorts A1 and B)

    Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-021 vs ARCT-165. Data are reported for the ARCT-021 arm (vs ARCT-165 values).

    Time frame: Days 29, 57, 209, Final Visit (approx. Day 394) for Cohort A1, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B

  12. SARS-CoV-2 Full-length Spike and Receptor-binding Domain (RBD) Binding Antibody Levels, Expressed as GMCs

    Spike binding antibody levels expressed as GMCs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibodies for ancestral strain.

    Time frame: Baseline and Day 57 for Cohorts A1 and A2, Baseline and Day 15 for Cohort B

  13. Changes in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels, Expressed as GMFRs

    Spike binding antibody levels expressed as GMFRs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibody levels expressed as GMFR for ancestral strain.

    Time frame: Day 57 for Cohorts A1 and A2, Day 15 for Cohort B

  14. Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels

    Data are reported for ancestral, D614G, and B.1.351 variants for Spike binding antibodies and ancestral for RBD binding antibodies.

    Time frame: Day 57 for Cohorts A1 and A2, Day 15 for Cohort B

07

Results

Posted Oct 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Started444618121212
Received at least 1 dose of study drug444618121212
Completed42451791212
Not completed02011300
Withdrew: Withdrawal by subject01010200
Withdrew: Lost to follow-up01001100

Outcome measures

PrimaryNumber of Participants Reporting Solicited Local or Systemic Adverse Events (AEs)

Solicited local AEs were defined as injection site erythema, injection site pain, injection site induration, and injection site tenderness. Solicited systemic AEs were defined as arthralgia, chills, diarrhea, dizziness, fatigue, fever (categorized by measured body temperature), headache, myalgia, nausea and vomiting. Data are reported for the number of participants with solicited local and solicited systemic AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to Day 8 (7 days after first vaccine administration for Cohorts A1, A2 and B), and up to Day 36 (7 days after second vaccine administration for Cohorts A1 and A2)
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs)
ParticipantsCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Any Solicited Local AE After Dose 1343510121010
Any Solicited Local AE After Dose 2224610———
Any Solicited Systemic AE After Dose 13315912911
Any Solicited Systemic AE After Dose 2223510———
PrimaryNumber of Participants Reporting Unsolicited AEs

Unsolicited AEs were defined as any spontaneously reported or discovered AE. Data are reported for the number of participants with unsolicited AEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to Day 29 (28 days after vaccine administration for Cohort B), and up to Day 57 (up to 28 days after each vaccine administration for Cohorts A1 and A2)
Reported as:
Count of participants · Participants
Number of Participants Reporting Unsolicited AEs
ParticipantsCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Number of Participants Reporting Unsolicited AEs3324159910
PrimaryNumber of Participants Reporting Medically Attended Adverse Events (MAAEs), AEs Leading to Discontinuation From Study Vaccine/Study Withdrawal, or Serious Adverse Events (SAEs)

An MAAE was an AE that led to an unscheduled visit (including a telemedicine visit) with a health care provider (HCP) (e.g., nurse, nurse practitioner, physician's assistant, physician), including visits to a study site for unscheduled assessments (e.g., rash assessment, abnormal laboratory follow up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the study site (e.g., urgent care, primary care physician). An SAE was defined as any event that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Through Final Visit (365 days after last study vaccine dose); up to a maximum of approximately 394 days
Reported as:
Count of participants · Participants
Number of Participants Reporting Medically Attended Adverse Events (MAAEs), AEs Leading to Discontinuation From Study Vaccine/Study Withdrawal, or Serious Adverse Events (SAEs)
ParticipantsCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Any MAAEs01013210
Any AEs Leading to Discontinuation from Study Vaccine/Study Withdrawal00000000
Any SAEs00010100
PrimarySevere Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Concentration (GMC)

Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral D614G variant. Data are reported in international units per milliliter (IU/mL).

Time frame:
Baseline, Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2; Baseline, Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Geometric mean · IU/mL
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Concentration (GMC)
IU/mLCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Pseudoviral D614G; Baseline8 (NA to NA)8 (6 to 11)12 (4 to 33)421 (74 to 2383)455 (202 to 1028)87 (51 to 148)94 (29 to 301)114 (58 to 224)
Pseudoviral D614G; Day 15—————1415 (927 to 2160)2019 (1179 to 3459)3474 (1577 to 7656)
Pseudoviral D614G; Day 2936 (0 to 2715)9 (2 to 47)26 (6 to 107)1966 (592 to 6534)1949 (1026 to 3701)1741 (1001 to 3028)2202 (1170 to 4145)4200 (2274 to 7757)
Pseudoviral D614G; Day 5742 (2 to 998)87 (0 to 1334270362)70 (11 to 452)2038 (676 to 6143)3563 (2083 to 6096)———
Pseudoviral D614G; Day 91—————1796 (1067 to 3024)1697 (840 to 3429)3427 (2113 to 5558)
Pseudoviral D614G; Day 181—————1072 (450 to 2551)1534 (552 to 4260)3041 (1334 to 6932)
Pseudoviral D614G; Day 20990 (2 to 3976)—19 (4 to 85)1340 (100 to 17882)1402 (819 to 2402)———
Pseudoviral D614G; Day 271—————611 (246 to 1518)2158 (1198 to 3888)1965 (789 to 4893)
Pseudoviral D614G; Final Visit Cohort B (approx. Day 366)—————564 (232 to 1370)1924 (374 to 9900)2463 (870 to 6976)
Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394)60 (2 to 2088)—14 (0 to 3129)1000 (10 to 100036)1324 (671 to 2609)———
PrimarySARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMC

Blood samples were collected to assess participants' immune response. GMC data are reported for the pseudoviral B.1.351 (beta) variant. Data are reported in arbitrary units per milliliter (AU/mL).

Time frame:
Baseline, Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2; Baseline, Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Geometric mean · AU/mL
SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMC
AU/mLCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Pseudoviral B.1.351 (Beta); Baseline14 (NA to NA)14 (NA to NA)14 (13 to 15)402 (92 to 1761)442 (187 to 1042)38 (21 to 70)44 (15 to 130)60 (31 to 117)
Pseudoviral B.1.351 (Beta); Day 15—————554 (370 to 829)1479 (824 to 2652)1692 (905 to 3162)
Pseudoviral B.1.351 (Beta); Day 2917 (7 to 45)32 (0 to 1385422)17 (12 to 24)1926 (788 to 4710)1273 (615 to 2634)664 (447 to 986)1608 (940 to 2749)1768 (1061 to 2948)
Pseudoviral B.1.351 (Beta); Day 5721 (6 to 75)452 (0 to 1024516559)27 (10 to 71)2292 (991 to 5300)3237 (2123 to 4936)———
Pseudoviral B.1.351 (Beta); Day 91—————560 (326 to 960)1079 (559 to 2083)1376 (838 to 2260)
Pseudoviral B.1.351 (Beta); Day 181—————400 (142 to 1126)708 (219 to 2293)1202 (512 to 2819)
Pseudoviral B.1.351 (Beta); Day 20997 (3 to 3668)—14 (13 to 16)1372 (185 to 10163)1438 (780 to 2652)———
Pseudoviral B.1.351 (Beta); Day 271—————175 (30 to 1036)829 (252 to 2724)1129 (446 to 2858)
Pseudoviral B.1.351 (Beta); Final Visit Cohort B (approx. Day 366)—————213 (60 to 763)1532 (389 to 6036)1578 (604 to 4122)
Pseudoviral B.1.351 (Beta); Final Visit Cohort A1 and A2 (approx. Day 394)61 (3 to 1082)—14 (NA to NA)1502 (45 to 50296)847 (467 to 1535)———
PrimarySARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Fold Rise (GMFR)

Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral D614G variant.

Time frame:
Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Geometric mean · ratio
SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as Geometric Mean Fold Rise (GMFR)
ratioCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Pseudoviral D614G; Day 15—————16 (9 to 30)22 (9 to 50)28 (11 to 67)
Pseudoviral D614G; Day 294.6 (0.1 to 346.2)1.0 (0.6 to 1.7)2.2 (0.4 to 12.2)4.7 (1.4 to 15.9)4.4 (2.7 to 7)20 (10 to 41)24 (10 to 54)37 (17 to 77)
Pseudoviral D614G; Day 575.4 (0.2 to 127.2)10.1 (0 to 48765966.9)5.9 (0.5 to 65)4.8 (1.2 to 19.0)6.2 (3.8 to 10)———
Pseudoviral D614G; Day 91—————20 (10 to 41)17 (8 to 36)30 (19 to 47)
Pseudoviral D614G; Day 181—————11 (4 to 30)12 (3 to 45)31 (14 to 70)
Pseudoviral D614G; Day 20911.4 (0.3 to 506.9)—1.4 (0.1 to 14.7)3.2 (0.7 to 14.2)2.7 (1.8 to 4.1)———
Pseudoviral D614G; Day 271—————5 (1 to 19)13 (2 to 71)20 (10 to 43)
Pseudoviral D614G; Final Visit Cohort B (approx. Day 366)—————6 (1 to 27)27 (5 to 147)25 (7 to 88)
Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394)7.7 (0.2 to 266.2)—0.8 (0 to 329524.9)2.7 (0.2 to 42.6)1.9 (1.1 to 3.3)———
PrimarySARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMFR

Blood samples were collected to assess participants' immune response. GMFR data are reported for the pseudoviral B.1.351 (beta) variant.

Time frame:
Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Geometric mean · ratio
SARS-CoV-2 Serum Neutralizing Antibody Levels, Expressed as GMFR
ratioCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Pseudoviral B.1.351 (Beta); Day 15—————14 (8 to 26)34 (16 to 72)25 (12 to 51)
Pseudoviral B.1.351 (Beta); Day 291.2 (0.5 to 3.2)2.3 (0 to 98958.7)1.2 (0.8 to 1.7)4.8 (1.6 to 14.0)3.2 (1.3 to 7.5)17 (10 to 31)37 (17 to 77)29 (16 to 54)
Pseudoviral B.1.351 (Beta); Day 571.5 (0.4 to 5.4)32.3 (0 to 73179754.2)1.9 (0.7 to 4.9)5.7 (1.4 to 22.7)5.6 (3.3 to 9.7)———
Pseudoviral B.1.351 (Beta); Day 91—————14 (7 to 27)23 (10 to 51)23 (15 to 35)
Pseudoviral B.1.351 (Beta); Day 181—————10 (4 to 26)12 (1 to 98)24 (10 to 56)
Pseudoviral B.1.351 (Beta); Day 2096.9 (0.2 to 262.0)—1.0 (NA to NA)2.8 (0.7 to 11.6)2.9 (1.8 to 4.6)———
Pseudoviral B.1.351 (Beta); Day 271—————4 (2 to 8)12 (2 to 71)23 (11 to 45)
Pseudoviral B.1.351 (Beta); Final Visit Cohort B (approx. Day 366)—————5 (1 to 22)46 (5 to 409)31 (9 to 108)
Pseudoviral B.1.351 (Beta); Final Visit Cohorts A1 and A2 (approx. Day 394)4.4 (0.2 to 77.3)—1.0 (0.6 to 1.5)3.0 (0.2 to 42.9)1.7 (0.9 to 3.2)———
PrimaryNumber of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral D614G Variant)

Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G variant.

Time frame:
Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Count of participants · Participants
Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral D614G Variant)
ParticipantsCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Pseudoviral D614G; Day 15—————111110
Pseudoviral D614G; Day 29102310111111
Pseudoviral D614G; Day 57212411———
Pseudoviral D614G; Day 91—————101012
Pseudoviral D614G; Day 181—————589
Pseudoviral D614G; Day 2092—015———
Pseudoviral D614G; Day 271—————368
Pseudoviral D614G; Final Visit Cohort B (approx. Day 366)—————356
Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394)2—011———
PrimaryNumber of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral B.1.351 [Beta] Variant)

Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral B.1.351 (beta) variant.

Time frame:
Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Count of participants · Participants
Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Serum Neutralizing Antibody Levels (Pseudoviral B.1.351 [Beta] Variant)
ParticipantsCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Pseudoviral B.1.351 (Beta); Day 15—————111110
Pseudoviral B.1.351 (Beta); Day 2901039111111
Pseudoviral B.1.351 (Beta); Day 5712139———
Pseudoviral B.1.351 (Beta); Day 91—————91012
Pseudoviral B.1.351 (Beta); Day 181—————488
Pseudoviral B.1.351 (Beta); Day 2092—015———
Pseudoviral B.1.351 (Beta); Day 271—————259
Pseudoviral B.1.351 (Beta); Final Visit Cohort B (approx. Day 366)—————347
Pseudoviral B.1.351 (Beta); Final Visit Cohorts A1 and A2 (approx. Day 394)2—011———
PrimaryGMC Ratio (ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154)

Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154. Data are reported for the ARCT-165 and ARCT-021 arms (vs ARCT-154 values).

Time frame:
Days 29, 57, 209, Final Visit (approx. Day 394) for Cohorts A1 and A2, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Geometric mean · ratio
GMC Ratio (ARCT-165 vs ARCT-154 and ARCT-021 vs ARCT-154)
ratioCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A2: ARCT-021Cohort B: ARCT-021Cohort B: ARCT-165
Pseudoviral D614G; Day 15———0.41 (0.179 to 0.924)0.58 (0.240 to 1.405)
Pseudoviral D614G; Day 291.38 (0.108 to 17.701)0.35 (0.054 to 2.225)1.01 (0.301 to 3.377)0.41 (0.190 to 0.903)0.52 (0.229 to 1.203)
Pseudoviral D614G; Day 570.60 (0.035 to 10.082)1.23 (0.046 to 33.164)0.57 (0.210 to 1.559)——
Pseudoviral D614G; Day 91———0.52 (0.269 to 1.021)0.50 (0.225 to 1.089)
Pseudoviral D614G; Day 181———0.35 (0.115 to 1.082)0.50 (0.151 to 1.686)
Pseudoviral D614G; Day 2094.65 (0.115 to 188.134)—0.96 (0.251 to 3.629)——
Pseudoviral D614G; Day 271———0.31 (0.086 to 1.123)1.10 (0.377 to 3.199)
Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394)4.20 (0.038 to 458.249)—0.76 (0.139 to 4.106)——
Pseudoviral D614G; Final Visit Cohort B (approx. Day 366)———0.23 (0.064 to 0.825)0.78 (0.162 to 3.771)
Pseudoviral B.1.351; Day 15———0.33 (0.165 to 0.650)0.87 (0.392 to 1.951)
Pseudoviral B.1.351; Day 291.03 (0.575 to 1.846)1.92 (0.426 to 8.609)1.51 (0.418 to 5.476)0.38 (0.204 to 0.691)0.91 (0.452 to 1.827)
Pseudoviral B.1.351; Day 570.78 (0.227 to 2.712)16.96 (1.632 to 176.241)0.71 (0.325 to 1.545)——
Pseudoviral B.1.351; Day 91———0.41 (0.205 to 0.808)0.78 (0.365 to 1.684)
Pseudoviral B.1.351; Day 181———0.33 (0.099 to 1.117)0.59 (0.155 to 2.238)
Pseudoviral B.1.351; Day 2096.77 (0.210 to 218.085)—0.95 (0.242 to 3.759)——
Pseudoviral B.1.351; Day 271———0.16 (0.032 to 0.742)0.73 (0.192 to 2.813)
Pseudoviral B.1.351; Final Visit Cohorts A1 and A2 (approx. Day 394)4.37 (0.102 to 187.648)—1.77 (0.433 to 7.256)——
Pseudoviral B.1.351; Final Visit Cohort B (approx. Day 366)———0.14 (0.034 to 0.540)0.97 (0.234 to 4.022)
Pseudoviral B.1.617.2; Day 15———0.43 (0.208 to 0.900)0.69 (0.293 to 1.611)
Pseudoviral B.1.617.2; Day 292.45 (0.183 to 32.786)0.77 (0.268 to 2.241)1.17 (0.386 to 3.544)0.47 (0.231 to 0.947)0.66 (0.305 to 1.447)
Pseudoviral B.1.617.2; Day 571.78 (0.293 to 10.846)1.42 (0.552 to 3.644)0.92 (0.345 to 2.469)——
Pseudoviral B.1.617.2; Day 91———0.68 (0.266 to 1.740)0.61 (0.277 to 1.331)
Pseudoviral B.1.617.2; Day 181———0.46 (0.142 to 1.466)0.82 (0.274 to 2.465)
Pseudoviral B.1.617.2; Day 2093.26 (0.388 to 27.333)—0.59 (0.116 to 3.053)——
Pseudoviral B.1.617.2; Day 271———0.41 (0.114 to 1.465)1.30 (0.482 to 3.497)
Pseudoviral B.1.617.2; Final Visit Cohorts A1 and A2 (approx. Day 394)2.18 (0.317 to 15.035)—0.84 (0.179 to 3.905)——
Pseudoviral B.1.617.2; Final Visit Cohort B (approx. Day 366)———0.35 (0.095 to 1.282)1.30 (0.279 to 6.100)
Pseudoviral BA.1 Variant; Day 15———0.34 (0.159 to 0.740)1.18 (0.501 to 2.799)
Pseudoviral BA.1 Variant; Day 291.52 (0.677 to 3.427)1.05 (0.832 to 1.336)1.18 (0.369 to 3.760)0.36 (0.182 to 0.703)1.06 (0.485 to 2.310)
Pseudoviral BA.1 Variant; Day 571.15 (0.612 to 2.153)9.73 (0.286 to 331.151)0.74 (0.287 to 1.913)——
Pseudoviral BA.1 Variant; Day 91———0.35 (0.182 to 0.666)0.82 (0.361 to 1.856)
Pseudoviral BA.1 Variant; Day 181———0.22 (0.047 to 1.032)0.82 (0.194 to 3.479)
Pseudoviral BA.1 Variant; Day 2098.15 (0.701 to 94.646)—1.38 (0.260 to 7.365)——
Pseudoviral BA.1 Variant; Day 271———0.20 (0.038 to 1.011)1.27 (0.369 to 4.347)
Pseudoviral BA.1 Variant; Final Visit Cohorts A1 and A2 (approx. Day 394)3.69 (0.190 to 71.730)—1.91 (0.223 to 16.385)——
Pseudoviral BA.1 Variant; Final Visit Cohort B (approx. Day 366)———0.11 (0.020 to 0.562)0.87 (0.162 to 4.620)
PrimaryGMC Ratio (ARCT-021 vs ARCT-165 Cohorts A1 and B)

Blood samples were collected to assess participants' immune response. Data are reported for the pseudoviral D614G Variant, B.1.351 Variant, B.1.617.2 Variant, BA.1 Variant for the GMC ratio of ARCT-021 vs ARCT-165. Data are reported for the ARCT-021 arm (vs ARCT-165 values).

Time frame:
Days 29, 57, 209, Final Visit (approx. Day 394) for Cohort A1, and Days 15, 29, 91, 181, 271 and Final Visit (approx. Day 366) for Cohort B
Reported as:
Geometric mean · ratio
GMC Ratio (ARCT-021 vs ARCT-165 Cohorts A1 and B)
ratioCohort A1: ARCT-021Cohort B: ARCT-021
Pseudoviral D614G; Day 15—0.70 (0.368 to 1.335)
Pseudoviral D614G; Day 294.00 (0.063 to 252.690)0.79 (0.358 to 1.746)
Pseudoviral D614G; Day 570.48 (0.004 to 53.354)—
Pseudoviral D614G; Day 91—1.06 (0.460 to 2.432)
Pseudoviral D614G; Day 181—0.70 (0.186 to 2.624)
Pseudoviral D614G; Day 209NA (NA to NA)—
Pseudoviral D614G; Day 271—0.28 (0.117 to 0.684)
Pseudoviral D614G; Final Visit Cohorts A1 and A2 (approx. Day 394)NA (NA to NA)—
Pseudoviral D614G; Final Visit Cohort B (approx. Day 366)—0.29 (0.062 to 1.377)
Pseudoviral B.1.351; Day 15—0.37 (0.192 to 0.731)
Pseudoviral B.1.351; Day 290.54 (0.061 to 4.779)0.41 (0.221 to 0.774)
Pseudoviral B.1.351; Day 570.05 (0.004 to 0.609)—
Pseudoviral B.1.351; Day 91—0.52 (0.232 to 1.160)
Pseudoviral B.1.351; Day 181—0.56 (0.122 to 2.616)
Pseudoviral B.1.351; Day 209NA (NA to NA)—
Pseudoviral B.1.351; Day 271—0.21 (0.037 to 1.223)
Pseudoviral B.1.351; Final Visit Cohorts A1 and A2 (approx. Day 394)NA (NA to NA)—
Pseudoviral B.1.351; Final Visit Cohort B (approx. Day 366)—0.14 (0.028 to 0.688)
Pseudoviral B.1.617.2; Day 15—0.63 (0.328 to 1.210)
Pseudoviral B.1.617.2; Day 293.16 (0.028 to 357.696)0.70 (0.365 to 1.357)
Pseudoviral B.1.617.2; Day 571.26 (0.053 to 29.735)—
Pseudoviral B.1.617.2; Day 91—0.68 (0.266 to 1.740)
Pseudoviral B.1.617.2; Day 181—0.56 (0.159 to 1.948)
Pseudoviral B.1.617.2; Day 209NA (NA to NA)—
Pseudoviral B.1.617.2; Day 271—0.31 (0.109 to 0.904)
Pseudoviral B.1.617.2; Final Visit Cohorts A1 and A2 (approx. Day 394)NA (NA to NA)—
Pseudoviral B.1.617.2; Final Visit Cohort B (approx. Day 366)—0.27 (0.065 to 1.097)
Pseudoviral BA.1 Variant; Day 15—0.29 (0.156 to 0.537)
Pseudoviral BA.1 Variant; Day 291.45 (0.304 to 6.868)0.34 (0.174 to 0.654)
Pseudoviral BA.1 Variant; Day 570.12 (0.003 to 4.660)—
Pseudoviral BA.1 Variant; Day 91—0.43 (0.182 to 0.996)
Pseudoviral BA.1 Variant; Day 181—0.27 (0.059 to 1.217)
Pseudoviral BA.1 Variant; Day 209NA (NA to NA)—
Pseudoviral BA.1 Variant; Day 271—0.15 (0.042 to 0.570)
Pseudoviral BA.1 Variant; Final Visit Cohorts A1 and A2 (approx. Day 394)NA (NA to NA)—
Pseudoviral BA.1 Variant; Final Visit Cohort B (approx. Day 366)—0.12 (0.024 to 0.622)
PrimarySARS-CoV-2 Full-length Spike and Receptor-binding Domain (RBD) Binding Antibody Levels, Expressed as GMCs

Spike binding antibody levels expressed as GMCs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibodies for ancestral strain.

Time frame:
Baseline and Day 57 for Cohorts A1 and A2, Baseline and Day 15 for Cohort B
Reported as:
Geometric mean · AU/mL
SARS-CoV-2 Full-length Spike and Receptor-binding Domain (RBD) Binding Antibody Levels, Expressed as GMCs
AU/mLCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Baseline; RBD (Ancestral)0.0 (0.0 to 0.0)0.1 (0.0 to 1.2)0.1 (0.0 to 0.7)34 (9 to 124)29 (14 to 60)9 (6 to 14)9 (4 to 21)10 (6 to 16)
Baseline; Spike (Ancestral)0.0 (0.0 to 0.2)0.0 (0.0 to 0.4)0.3 (0.0 to 1.7)44 (13 to 156)49 (27 to 90)18 (12 to 27)17 (8 to 39)19 (11 to 33)
Baseline; Spike (D614G)0.0 (0.0 to 0.2)0.1 (0.0 to 0.9)0.2 (0.0 to 1.7)47 (14 to 161)52 (29 to 95)19 (13 to 27)18 (8 to 40)20 (11 to 35)
Baseline; Spike (B.1.351)0.0 (0.0 to 0.2)0.0 (0.0 to 0.5)0.2 (0.0 to 1.6)30 (11 to 77)32 (19 to 56)8 (6 to 12)8 (4 to 17)9 (5 to 16)
Day 57; RBD (Ancestral)3.4 (0.1 to 133.7)34.5 (0.0 to 13491400)8.2 (1.2 to 54.5)138 (49 to 386)186 (128 to 270)———
Day 57; Spike (Ancestral)10.6 (0.4 to 285.1)52.4 (0.0 to 3217076.2)19.1 (3.3 to 108.8)181 (65 to 504)265 (196 to 358)———
Day 57; Spike (D614G)10.7 (0.4 to 276.8)55.8 (0.0 to 1948962.5)19.8 (3.6 to 110.4)187 (69 to 511)277 (205 to 375)———
Day 57; Spike (B.1.351)5.0 (0.2 to 147.4)61.1 (0.0 to 7370140.4)5.8 (0.6 to 58.4)119 (51 to 278)147 (112 to 193)———
Day 15; RBD (Ancestral)—————91 (57 to 146)171 (115 to 254)221 (118 to 415)
Day 15; Spike (Ancestral)—————138 (89 to 215)231 (150 to 355)290 (164 to 514)
Day 15; Spike (D614G)—————142 (92 to 217)235 (154 to 359)296 (166 to 529)
Day 15; Spike (B.1.351)—————57 (40 to 82)117 (79 to 172)123 (71 to 212)
PrimaryChanges in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels, Expressed as GMFRs

Spike binding antibody levels expressed as GMFRs are reported for ancestral, D614G, and B.1.351 variants and RBD binding antibody levels expressed as GMFR for ancestral strain.

Time frame:
Day 57 for Cohorts A1 and A2, Day 15 for Cohort B
Reported as:
Geometric mean · ratio
Changes in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels, Expressed as GMFRs
ratioCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Day 57; RBD (Ancestral)129 (6 to 2894)286 (0 to 46860600000)110 (8 to 1560)4.1 (1.4 to 12.3)4.9 (3.0 to 8.0)———
Day 57; Spike (Ancestral)231 (10 to 5236)807 (0 to 184116000000)76 (5 to 1279)4.1 (1.6 to 10.8)4.2 (2.8 to 6.3)———
Day 57; Spike (D614G)237 (10 to 5730)667 (0 to 2176320000000)84 (5 to 1404)4.0 (1.5 to 10.4)4.1 (2.8 to 6.1)———
Day 57; Spike (B.1.351)136 (5 to 4083)1076 (0 to 12500400000000)32 (3 to 361)4.0 (1.6 to 10.2)3.6 (2.4 to 5.4)———
Day 15; RBD (Ancestral)—————10 (6 to 16)19 (10 to 38)21 (11 to 40)
Day 15; Spike (Ancestral)—————8 (5 to 13)13 (7 to 25)14 (8 to 26)
Day 15; Spike (D614G)—————8 (5 to 13)13 (7 to 25)14 (7 to 26)
Day 15; Spike (B.1.351)—————7 (4 to 11)15 (8 to 27)13 (7 to 22)
PrimaryNumber of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels

Data are reported for ancestral, D614G, and B.1.351 variants for Spike binding antibodies and ancestral for RBD binding antibodies.

Time frame:
Day 57 for Cohorts A1 and A2, Day 15 for Cohort B
Reported as:
Count of participants · Participants
Number of Participants Achieving Greater Than or Equal to 4-fold Rise From Before Vaccination in SARS-CoV-2 Full-length Spike and RBD Binding Antibody Levels
ParticipantsCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Day 57; RBD (Ancestral)42439———
Day 57; Spike (Ancestral)42438———
Day 57; Spike (D614G)42438———
Day 57; Spike (B.1.351)42436———
Day 15; RBD (Ancestral)—————111110
Day 15; Spike (Ancestral)—————91010
Day 15; Spike (D614G)—————91110
Day 15; Spike (B.1.351)—————91110

Adverse events

Collected over Through Final Visit (365 days after last study vaccine dose); up to a maximum of approximately 394 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A1: ARCT-0210/4 (0%)0/4 (0%)3/4 (75%)
Cohort A1: ARCT-1650/4 (0%)0/4 (0%)3/4 (75%)
Cohort A1: ARCT-1540/4 (0%)0/4 (0%)2/4 (50%)
Cohort A2: ARCT-0210/6 (0%)1/6 (16.7%)4/6 (66.7%)
Cohort A2: ARCT-1540/18 (0%)0/18 (0%)15/18 (83.3%)
Cohort B: ARCT-0210/12 (0%)1/12 (8.3%)9/12 (75%)
Cohort B: ARCT-1650/12 (0%)0/12 (0%)9/12 (75%)
Cohort B: ARCT-1540/12 (0%)0/12 (0%)10/12 (83.3%)
Most frequent serious events
Most frequent serious events
EventCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Spontaneous abortionPregnancy, puerperium and perinatal conditions0/30/10/21/40/100/90/60/7
DepressionPsychiatric disorders0/40/40/40/60/181/120/120/12
Most frequent other events
Showing 10 of 52
Most frequent other events
EventCohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154
Upper respiratory tract infectionInfections and infestations0/40/40/44/615/180/121/122/12
COVID-19Infections and infestations0/40/40/42/66/184/126/126/12
CoughRespiratory, thoracic and mediastinal disorders2/41/40/41/61/182/120/122/12
Nasal congestionRespiratory, thoracic and mediastinal disorders2/41/40/41/60/182/121/122/12
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/40/40/40/62/182/121/121/12
HeadacheNervous system disorders2/40/40/41/65/181/121/121/12
FatigueGeneral disorders2/40/40/40/61/181/121/121/12
NeutropeniaBlood and lymphatic system disorders0/42/41/40/62/182/121/122/12
Fungal infectionInfections and infestations0/40/41/40/60/180/120/120/12
PericoronitisInfections and infestations1/40/40/40/60/180/120/120/12

Baseline characteristics

Measured in the Safety Set (SS): The SS included all randomized participants who received at least one dose of the study vaccine. Assignment of participants to study vaccine group was based on the study vaccine actually received.

Age, Continuous
Age, Continuous(years)Cohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154Total
Mean46 ± 1734 ± 1050 ± 1733 ± 931 ± 844 ± 1650 ± 1344 ± 1341 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154Total
Female31241096742
Male1322836530
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154Total
Hispanic or Latino000012003
Not Hispanic or Latino44461710121269
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A1: ARCT-021Cohort A1: ARCT-165Cohort A1: ARCT-154Cohort A2: ARCT-021Cohort A2: ARCT-154Cohort B: ARCT-021Cohort B: ARCT-165Cohort B: ARCT-154Total
American Indian or Alaska Native000000000
Asian0220022210
Native Hawaiian or Other Pacific Islander000000000
Black or African American11151612027
White20112981033
More than one race110000002
Unknown or Not Reported000000000
08

Study locations

4 sites
  • Arcturus Investigational Site 202
    Wichita, Kansas 67207, United States
  • Arcturus Investigational Site 201
    Kansas City, Missouri 64114, United States
  • Arcturus Investigational Site 101
    Singapore, 169608, Singapore
  • Arcturus Investigational Site 301
    Diepkloof, Soweto 1862, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will only be made available to study investigators at this time.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Dec 2023, 27 months.

Results were first posted in Oct 2025, 1 year 9 months after primary completion. A results delay was requested in Dec 2024.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 27 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 8, 2021
StartActual
Aug 30, 2021
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 19, 2023
Results delay requested
Dec 16, 2024
Results first posted
Oct 15, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05037097
Lead sponsor
Arcturus Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2021
Start date
Aug 30, 2021
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023
Results posted
Oct 15, 2025
Last update
Oct 15, 2025

Study contacts

Clinical Program Director
study director · Arcturus Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SARS-CoV-2 mRNA Vaccine ARCT-021

Start the discussion